As recent studies have found, severe COVID-19 is commonly complicated with coagulopathy, including disseminated intravascular coagulation and venous thromboembolism [33,34]. For this reason, the administration of heparin has been recommended for COVID-19 patients according to expert consensus [4,31], although its efficacy remains to be validated. In a study of 449 patients with severe COVID-19 and sepsis-induced coagulopathy criteria or with markedly elevated D-dimer levels (higher than sixfold of upper limit of normal), anticoagulant therapy, mainly with low-molecular-weight heparin, was associated with better prognosis [34]. Beyond severe coagulopathy, special attention to venous thromboembolism prophylaxis is necessary in the management of COVID-19 [35]. Low-molecular-weight heparin is preferred over unfractionated heparin in order to reduce patient contact (depending on the patient’s bleeding risk and creatinine clearance) [36]. We found that all protocols analyzed included anticoagulant treatment, with low-molecular-weight heparin as the first option. It was recommended that all hospitalized COVID-19 patients receive prophylactic heparin. This recommendation was extended to after discharge if necessitated by the patient’s clinical condition in 46.6% of protocols. An increase in prophylactic heparin doses was recommended in 53.3% of the protocols for patients at high risk of thrombosis. In five protocols (33.3%), heparin was increased to therapeutic doses if the condition was critical or if there was a progressive increase in D-dimer levels. All protocol included therapeutic heparin if there was evidence of venous thromboembolism.